Figure 1: Manhattan plot of stage 1 GWAS analysis of BCC from 23andMe data set.
From: Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma
Total stage 1 GWAS analysis included 12,945 cases and 274,252 controls. Loci with smallest P<10−6 (28 total, logistic regression) are labelled with the name of the nearest gene. Positions with P<5 × 10−8 (genome-wide significance) are shown in red. In stage 1, ten novel BCC susceptibility loci reached genome-wide significance after adjusting for genomic control, all of which are labelled in the figure with asterisks: from left to right, 3p13 (FOXP1), 3q28 (LPP), 6p21.32 (HLA-DQA2), 6p21.33 (HLA-B), 7p12.3 (TNS3), 7q22.1 (CUX1), 8q21.13 (ZBTB10), 9p22.2 (near BNC2), 19p13.3 (PLIN3), 21q22.3 (LINC00111). Four additional novel susceptibility loci—6p21.3 (NEU1), 10q24.3 (OBFC1), 6q27 (MIR3939), 6p22.3(CASC15)—were genome-wide significant in the overall meta-analysis (Table 2) and thus are not labelled in the figure.
